Update on drug-eluting coronary stents

References

• Jemal A, Murray T, Ward E et al. Cancer Statistics 2005. CA Cancer J. Clin. 55, 1030 (2005).
   Google Scholar
• Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J. Am. Coll. Cardiol. 12, 616–623 (1988).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 98, 1802–1820 (1998).
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 331, 496–502 (1994).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Foley DP, Suttorp M-J et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions. JACC 39, 393–399 (2002).
   Google Scholar
• Van den Brand M, Rensing J, Morel MM et al. The effect of completeness of revascularization on event-free survival at one-year in the ARTS trial. JACC 39, 559–564 (2002).
   Google Scholar
• El-Omar MM, Dangas G, Iakovou I et al. Update on in-stent restenosis. Curr. Interv. Card. Reports3, 296–305 (2001).
   PubMedGoogle Scholar
• Faries PL, Rohan DI, Takahara H et al. Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration. J. Vasc. Surg. 33(3), 601–607 (2001).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773 (2002).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Degertekin M, Tanabe K et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 106, 798 (2002).
   PubMed Web of Science ®Google Scholar
• Regar E, Serruys PW, Bode C et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106, 1949 (2002).
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349, 1315 (2003).
   PubMedGoogle Scholar
• Holmes DR, Leon MB, Moses JW et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109, 634–640 (2004).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Moses JW, Leon MB et al. Durable clinical benefit following Cypher coronary stent deployment: SIRIUS study 2-year results. Circulation 108, IV–532 (2003).
   Google Scholar
• Sousa JE, Costa MA, Abizaid A et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 111(18), 2326–2329 (2005).
   PubMed Web of Science ®Google Scholar
• Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E–SIRIUS). Lancet 362, 1093 (2003).
   PubMed Web of Science ®Google Scholar
• Schampaert E, Cohen EA, Schluter M et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C–SIRIUS). J. Am. Coll. Cardiol.43, 1110 (2004).
   PubMed Web of Science ®Google Scholar
• Babapulle MN, Joseph L, Belisle P et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet364, 583 (2004).
   PubMedGoogle Scholar
• Grube E, Silber S, Hauptmann KE et al. TAXUS-1: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation107, 38–42 (2003).
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki, J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation108, 788 (2003).
   PubMed Web of Science ®Google Scholar
• Silber S, Colombo A, Banning A et al. TAXUS II: prolonged clinical follow-up after thienopyridine withdrawal. JACC 45(3 Suppl. A), 34A (2005).
   Google Scholar
• Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221 (2004).
   Google Scholar
• Stone GW, Ellis, SG,et al. Cox, DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109, 1942 (2004).
   PubMed Web of Science ®Google Scholar
• Ellis S, Stone GW, Cox DA et al. Durability of the polymer-based, paclitaxel-eluting TAXUS stent in key patient subset: two-year results from the TAXUS IV trial. ACC 2005. JACC 45(3 Suppl. A), 49A (2005).
   Google Scholar
• Lemos PA, Serruys PW, van Domburg RT et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ‘real world’: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109, 190 (2004).
   PubMed Web of Science ®Google Scholar
• Lemos PA, Hoye A, Goedhard D et al. Clinical, angiographic and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantationin complex patients. Circulation 109, 1366–1370 (2004).
   PubMed Web of Science ®Google Scholar
• Domburg RT, Ong AT, Lemos PA et al. Two year outcome of the RESEARCH registry ACC 2005. JACC 45(3 Suppl. A), 74A (2005).
   Google Scholar
• Urban PM, Gershlick A, Guagliumi G et al. MACE predictors after implantation of sirolimus-eluting stents: a report from the e-CYPHER Registry. Am. J. Card. 94(Suppl. 6), 68E (2004).
   Google Scholar
• Abizaid A, Chan C, Lim YT et al. WISDOM high-risk subgroups: 12-month outcomes with the slow release, polymer based, paclitaxel-eluting TAXUS stents. Am. J. Card. 94(Suppl. 6), 70E (2004).
   Google Scholar
• Abizaid A, Chan C, Lim TT et al. WISDOM high-risk subgroups: 12-month outcomes with the slow-release, polymer-based, paclitaxel-eluting taxus stent. JACC45(3 Suppl. A), 84A (2005).
   Google Scholar
• Ong AT, Serruys PW, Aoki J et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J. Am. Coll. Cardiol.45(7), 1135–1141 (2005).
   PubMed Web of Science ®Google Scholar
• Ribichini F, Tomai F, DiSciascio G et al. Dexamethasone-eluting stent Italian registry in acute coronary syndromes. Preliminary results of the nationwide DESIRE Study. Am. J. Card. 94(Suppl. 6), 71E (2004).
   Google Scholar
• Feres F, Daher V, Abizaid A et al. Cypher™ versus Taxus™ Stent in very complex coronary lesions. A volumetric analisis of in-stent intimal hyperplasia. JACC 45(3 Suppl. A), 75A (2005).
   Google Scholar
• Windecker S, Remondino A, Wenawaser P et al. A Randomized Comparison of a Sirolimus With a Paclitaxel Eluting Stent For Coronary Revascularization: The SIRTAX Trial. JACC 45(3 Suppl. A), 7A (2005).
   Google Scholar
• Iakovou I, Schmidt T, Grube E et al. Incidence and predictors of stent thrombosis after paclitaxel and sirolimus-eluting stent implantation in the real world. Am. J. Card. 94(Suppl. 6), 133E (2004).
   PubMedGoogle Scholar
• Nakamura S, Muthusamy TS, Bae JH et al. Comparison of efficacy and safety between sirolimus-eluting stent (Cypher™) and paclitaxel-eluting stent (TAXUS™) in unprotected left main coronary arteries: multicenter register in Asia. JACC 45(3 Suppl. A), 85A (2005).
   Google Scholar
• Wacinski P, Bilodeau L, Gallo et al. Drug-eluting stents in complex coronary lesions: comparison of sirolimus (Cypher™) and paclitaxel (Taxus) stents in clinical practice. Montreal Heart Institute Drug-Eluting Stents Registry (MUST). Am. J. Card. 94(Suppl. 6), 133E (2004).
   PubMedGoogle Scholar
• Nakamura S, Muthusamy TS, Bae JH et al. Comparison of efficacy and safety between sirolimus-eluting stent (Cypher™) and paclitaxel-eluting stent (TAXUS™) on the outcome of patients with chronic total oclusions: multicenter register in Asia. Am. J. Card. 94(Suppl. 6), 48E (2004).
   Google Scholar
• Park SJ, Kim JH, Lee SW et al. Multicenter prospective nonrandomized Registry study for drug-eluting stents in very long coronary lesions (Cypher vs.Taxus): Long drug-eluting stent study. Am. J. Card. 94(Suppl. 6), 134E (2004).
   Google Scholar
• Goy JJ, Stauffer JC, Siegenthaler M et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J. Am. Coll. Cardiol.45(2), 308–311 (2005).
   PubMed Web of Science ®Google Scholar
• Dzavik V, Ghali, WA, Norris, C et al. Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am. Heart J. 142, 119 (2001).
   Google Scholar
• Moussa I, Reimers B, Moses J et al. Long-term angiographic and clinical outcome of patients undergoing multivessel coronary stenting. Circulation96, 3873 (1997).
   PubMedGoogle Scholar
• Kornowski R, Mehran R, Satler LF et al. Procedural results and late clinical outcomes following multivessel coronary stenting. J. Am. Coll. Cardiol.33, 420 (1999).
   PubMed Web of Science ®Google Scholar
• Spertus JA, Nerella R, Kettlekamp R et al. Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery. Circulation (E-pub ahead of print) (2005).
   Google Scholar
• Kettelkamp R, House J, Garg M et al. Using the risk of restenosis as a guide to triaging patients between surgical and percutaneous coronary revascularization. Circulation 110(11 Suppl. 1), II50–II54 (2004).
   PubMedGoogle Scholar
• Grilli R, Taroni F. Empirical assessment of the impact of drug-eluting stents on the rate of use of coronary revascularization procedures. Int. J. Technol. Assess. Healthcare 20(3), 356–360 (2004).
   PubMedGoogle Scholar
• Powell BD, Rihal CS, Bell MR et al. Anticipated impact of drug-eluting stents on referral patterns for coronary artery bypass graft surgery: a population based angiographic analisis. Mayo Clin. Proc. 79, 769–772 (2004).
   PubMed Web of Science ®Google Scholar
• Griffiths H, Bakhai A, West D, Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary disease. Eur. J. Cardiothorac. Surg. 26(3), 528–534 (2004).
   PubMedGoogle Scholar
• Mikhail GW, Airoldi F, Tavano D. The use of drug eluting stents in single and multivessel disease: results from a single centre experience. Heart 90(9), 990–994 (2004).
   PubMedGoogle Scholar
• Serruys PW, Lemos PA, van Hout BA et al. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularization Therapies Study part II (ARTS II). Heart90, 995–998 (2004).
   PubMed Web of Science ®Google Scholar
• Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). Circulation 100, 1464 (1999).
   PubMed Web of Science ®Google Scholar
• Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 107, 149 (2003).
   PubMed Web of Science ®Google Scholar
• Chieffo A, Stankovic G, Bonizzoni E. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation (E-pub ahead of print) (2005).
   PubMedGoogle Scholar
• Valgimigli M, van Mieghem CA, Ong AT et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 111(11), 1383–1389 (2005).
   PubMed Web of Science ®Google Scholar
• Ehard M, Kato O, Ito S et al. Long-term prognosis of percutaneous intervention for the left main coronary artery: how to achieve an outcome as reliable as bypass surgery. Am. J. Card. 94(Suppl. 6), 3E (2004).
   Google Scholar
• Hong SJ, Lim DS, Seo HS, Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. Catheter Cardiovasc. Interv. 64(1), 75–81 (2005).
   PubMedGoogle Scholar
• Murphy GJ, Bryan AJ, Angelini GD. Hybrid coronary revascularization in the era of drug-eluting stents. Ann. Thorac. Surg. 78(5), 1861–1867 (2004).
   PubMedGoogle Scholar
• Gupta N, Debsikdar J, Brodie BR et al. Drug eluting stents versus bare metal stents in patients with ST elevation myocardial infarction: results from the STENT Registry. Am. J. Card. 94(Suppl. 6), 11E (2004).
   Google Scholar
• Sousa EJ, Abizaid A, Gershlick AH et al. Real world use of sirolimus-eluting stents in saphenous vein graft disease: data from the e-CYPHER registry. JACC 45(3 Suppl. A), 26A (2005).
   Google Scholar
• Ardissino D, Cavallini C, Bramucci E et al. Sirolimus-eluting versus uncoated stents for prevention of restenosis in small arteries: a randomized trial. JAMA 292, 2727–2734 (2004).
   PubMed Web of Science ®Google Scholar
• Lemos PA, Arampatzis CA, Saia F et al. Treatment of very small vessel with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH Registry). Am. J. Cardiol. 93, 633–636 (2004).
   PubMedGoogle Scholar
• Lotan C, Schofer J, Seth A et al. Sirolimus-eluting stent in chronic total occlusion. EuroPCR: The Paris Course on Revascularization. Paris, France. May (2004).
   Google Scholar
• Lotan C, Gershlick A, Guagliumi G et al. Treatment of Chronic Total Occlusion Wih the Sirolimus-eluting Stent – Results From the e-CYPHER Registry. JACC45(3 Suppl. A), 47A–48A (2005).
   Google Scholar
• Werner GS, Krack A, Schwarz G, Figulla HR. Paclitaxel-eluting stents for the treatment of Chronic Total Coronary Occlusion (PACTO Study): a matched-pair comparison with bare metal stents to assess safety and efficacy. Am. J. Card. 94(Suppl. 6), 76E (2004).
   Google Scholar
• Nakamura S, Mutsusamy TS, Bae JH et al. Comparison of efficacy and safety between sirolimus-eluting stent (Cypher) and paclitaxel-eluting stent (Taxus) on the outcome of patients with chronic total occlusion: Multicenter Registry of Asia. Am. J. Card. 94(Suppl. 6), 77–78E (2004).
   Google Scholar
• Chevalier B, Glatt B, Royer T et al. Placement of coronary stents in bifurcation lesions by the ‘culotte’ technique. Am. J. Cardiol. 82, 943 (1998).
   PubMedGoogle Scholar
• Moussa I, Leon MB, Lansky A et al. Treatment of coronary bifurcation lesions with sirolimus-eluting stents using the ‘crush technique’. Am. J. Card. 94(Suppl. 6), 109E (2004).
   Google Scholar
• Nakamura S, Muthusamy TS, Bae JH et al. Impact of sirolimus-eluting stents on the 1-year outcome of patients with bifurcation lesions: multicenter registry in Asia. Am. J. Card. 94(Suppl. 6), 110E (2004).
   Google Scholar
• Gwon HC, Hong MK, Jang JC, The early results of TAXUS kissing stenting in the bifurcation lesion. Am. J. Card. 94(Suppl. 6), 110E–111E (2004).
   Google Scholar
• Ormiston JA, Currie E, Webster MW. Drug-eluting stents for coronary bifurcations: insights into the crush technique. Catheter Cardiovasc. Interv. 63(3), 332–336 (2004).
   PubMedGoogle Scholar
• Wong CB, Hardin S. A novel technique for coronary bifurcation lesions: cutting balloons, drug-eluting stents and the kissing technique. J. Invasive Cardiol. 17(2), 108–110 (2005).
   PubMedGoogle Scholar
• Lee BK, Kim YH, Kim MK et al. Comparison of simple versus complex techniques with sirolimus-eluting stent for bifurcation coronary lesions. JACC 45(3 Suppl. A), 55A (2005).
   Google Scholar
• van Belle E, Bauters C, Hubert E et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 96, 1454–1460 (1997).
   PubMed Web of Science ®Google Scholar
• Detre KM, Guo P, Holubkov R et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization investigation (BARI). Circulation 99, 633–640 (1999).
   PubMed Web of Science ®Google Scholar
• van Belle E, Perie M, Braune D et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients J. Am. Coll. Cardiol.40, 213–217 (2002).
   Google Scholar
• Beckman J, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA287, 2570–2581 (2002).
   PubMed Web of Science ®Google Scholar
• Moses JM, Leon MB, Popma JJ et al. Matched comparison of direct stenting to predilation with the sirolimus-eluting Bx velocity stent. J. Am. Coll. Cardiol. 43, 97A (2004).
   Google Scholar
• Guagliumi G, Urban P, Wijns W. Real world experience in treating diabetic patients with sirolimus-eluting stent implantation: a 6-month follow-up report from the international e-CYPHER Registry. Am. J. Card. 94(Suppl. 6), 73E (2004).
   Google Scholar
• Gupta N, Debsikdar., Brodie BR et al. Drug eluting stents vs. bare metal stents in patients with non-ST elevation myocardial infarction: results from the STENT Registry. Am. J. Card. 94(Suppl. 6), 11E (2004).
   Google Scholar
• Waksman R, White RL, Chan RS et al. Intracoronary γ-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 101, 2165–2171 (2000).
   PubMed Web of Science ®Google Scholar
• Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary γ-radiation therapy to inhibit the reccurance of restenosis after stenting. N. Engl. J. Med. 344, 250–256 (2001).
   PubMed Web of Science ®Google Scholar
• Grube E, Serruys PW, Russel ME et al. TAXUS III three-year clinical results: a feasibility study of the polymer-based, paclitaxel-coated stent for the treatment of in-stent restenosis. ACC 2005. JACC 45(3 Suppl. A), 68A (2005).
   Google Scholar
• Desmet W, Fuellgraf D, Neumann FJ et al. The 9-month results of the TROPICAL Study: a multicenter nonrandomized study of the CYPHER sirolimus-eluting stent in the treatment of patients with an in-stent restenotic native coronary artery lesion. Am. J. Card. 94(6 Suppl.), 55E (2004).
   PubMedGoogle Scholar
• Stone GW, Ellis SG, O’Shaughnessy et al. A prospective, multicenter randomized trial of the Paclitaxel-Eluting Stent Versus Vascular Brachytherapy in Patients with Coronary In-Stent Restenosis: The TAXUS-V ISR Trial. JACC 45(3Suppl. A), 83A (2005).
   Google Scholar
• Kastrati A, Mehilli J, von Beckerath N, Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA293(2), 165–171 (2005).
   PubMed Web of Science ®Google Scholar
• Hausleiter J, Kastrati A, Schuehlen H et al. Efficacy of Drug-Eluting Stents in the Treatment of Patients With In-Stent Restenosis and Diabetes mellitus. Results of the Randomized ISAR-DESIRE Trial. ACC 2005. JACC 45(3 Suppl. A), 8A (2005).
   Google Scholar
• Radke PW, Kobella S, Kaiser A et al. Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched comparison with intracoronary β-radiation therapy. Am. J. Card. 94(Suppl. 6), 56E (2004).
   Google Scholar
• Berenguer A, Mainar V, Bordes P et al. Low reccurence rate and good outcomes after sirolimus eluting stent implantation for in-stent restenosis: a prospective study with clinical and angiographic follow-up and analysis of predictors of recurrence. Am. J. Card. 94(Suppl. 6), 56E (2004).
   Google Scholar
• Mendiz OA, Valdivieso LR, Costantini RA et al. Drug-eluting stent versus conventional percutaneous transluminal coronary angioplasty for in-stent restenosis. Am. J. Card. 94(Suppl. 6), 57E (2004).
   Google Scholar
• Cutlip DE, Baim DS, Ho KK et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trails. Circulation 103, 1967–1971 (2001).
   PubMed Web of Science ®Google Scholar
• Bavry AA, Kumbhani DJ, Helton TJ et al. Sirolimus-eluting stents may decrease stent thrombosis: a meta-analisis of randomized clinical trials and the Cleveland Clinic Experience ACC 2005. JACC 45(3 Suppl. A), 35A (2005).
   Google Scholar
• Jeremias A, Sylvia B, Bridges J et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation109, 1930 (2004).
   PubMed Web of Science ®Google Scholar
• Regar E, Lemos PA, Saia F et al. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. Am. J. Cardiol. 93, 1271 (2004).
   PubMed Web of Science ®Google Scholar
• Chieffo A, Bonizzoni E, Orlic D et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 109, 2732 (2004).
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Ge L et al. Incidence and predictors of thrombosis after implantation of drug-eluting stents in unselected patients. ACC 2005. JACC 45(3 Suppl. A), 35A (2005).
   Google Scholar
• Moreno R, Fernandez C, Hernandez R et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J. Am. Coll. Cardiol.45(6), 954–959 (2005).
   PubMed Web of Science ®Google Scholar
• McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364, 1519–1521 (2004).
   PubMed Web of Science ®Google Scholar
• Meucci F, Falchetti E, Vittori G et al. increased risk of subacute thrombosis after overlapping with drug-eluting stents: an analisis from the Real-world Eluting Stent Comparative Italian Retrospective Evaluation (RECIPE) Study. ACC 2005. JACC 45(3 Suppl. A), 34A–35A (2005).
   Google Scholar
• Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation100(18), 1872–1878 (1999).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Russel ME. Paclitaxel-eluting coronary stents. Letter to editor. N. Engl. J. Med. 20, 2099–2100 (2004).
   Google Scholar
• Grube E, Sonoda S, Ikeno F et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109, 2168 (2004).
   PubMed Web of Science ®Google Scholar
• Storger H, Grube E, Hofmann M et al. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. J. Interv. Cardiol. 17(6), 387–390 (2004).
   PubMedGoogle Scholar
• Tuschiya Y, Lansky AJ, Costa RA et al. The effect of everolimus-eluting stents in different vessel sizes – results from the FUTURE 1 and 2 Trials. ACC 2005. JACC45(3 Suppl. A), 85A (2005).
   Google Scholar
• Di Mario C, Griffiths H, Goktekin O et al., Drug-eluting bioabsorbable magnesium stent. J. Interv. Cardiol.17(6), 391–395 (2004).
   PubMedGoogle Scholar
• Cho HJ, Kim TJ, Zhang SY et al. The effect of stem cell mobilization by granulocytes-colony stimulation factor on neointimal hyperplasia after vascular stenting: drug-eluting stent… is the solution in stem cell clinical trial? ACC 2005. JACC 45(3 Suppl. A), 42A (2005).
   Google Scholar
• Aoki J, Serruys PW, vanBeusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First in Man) Registry. J. Am. Coll. Cardiol. 45(10), 1574–1579 (2005)
   PubMed Web of Science ®Google Scholar
• Abizaid A, Albertal, M, Costa, MA et al. First human experience with the 17-β-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J. Am. Coll. Cardiol. 43, 1118 (2004).
   PubMed Web of Science ®Google Scholar
• Kipshidze N, Overlie P, Dunlap T et al. First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: six-month clinical and angiographic follow-up from AVAIL study. Abstracts from Scientific Sessions 2004. New Orleans, Louisiana, 7–10 November 2004.
   Google Scholar